Sorrento Therapeutics Inc (SRNE)

[dia76ca]

SORRENTO COVID,IMMUNOTHERAPY, PAIN AND LYMPHATIC DELIVERY PROGRAMS
COVID-19 PROGRAMS
Key Programs (Indication) Phase
COVISTIX™ (diagnostic) FDA EUA
COVIMARK™ (diagnostic) FDA EUA
VIREX (diagnostic) PH III
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
OVYDSO (Olgotrelvir) Ph II
Omicron mRNA Vaccine Preclinical

IMMUNOTHERAPY PROGRAMS
Key Programs (Indication) Phase
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Preclinical
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Solid Tumors) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, and esophageal) Ph I
TROP2 ADC* (Solid Tumors) Ph I
Seprehvec™ oncolytic virus (Solid Tumors; CNS Tumors) PH I
BCMA ADC (Liquid Tumors) Preclinical
Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I
Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma

PAIN PROGRAMS
Key Programs (Indication) Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
Gloperba® 1.8% Treatment of Gout (Oral) FDA Approval
SEMDEXA (SP-102) Ph III
SP-103 (Lidocaine Topical System 5.4%) Ph II
SP-104 (Delayed Burst Low Dose Naltrexone) Preclinical
RTX (resiniferatoxin) Epidural injection Ph II
RTX (resiniferatoxin) Intra-articular route Ph II

LYMPHATIC DELIVERY PROGRAM
Key Programs (Indication) Phase
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I